Latest From Biotech Now

Doping Undermines the Mission of Biotechnology

Sochi Flame

The Olympic Games in Sochi captures the world’s attention as athletes compete to bring home gold. Our industry plays a key role in helping to maintain the integrity and honor of sports and competition by remaining vigilant in our anti-doping efforts. Doping undermines the integrity of our industry’s core mission of serving patients through drug discovery and development. The same medicines that can be used to help children with devastating genetic deficiencies and growth disorders, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What’s New in RNAi Therapeutics?

87881842

At the 16th Annual BIO CEO & Investor Conference​, Monday morning’s therapeutic workshop, “Delivering the (RNAi) Goods,” featured a panel discussion moderated by Thomas Wei, senior research analyst at Jeffries LLC. The panel gave investors a peek into the novel approaches utilized by four leading companies in this area: Dicerna Pharmaceuticals, Arrowhead Research Corporation, Alnylam Pharmaceuticals, and Regulus Therapeutics. RNAi therapeutics, which include gene silencing, exon skipping, and mircroRNA therapy, are a promising area in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

Pops

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech Investors, Emerging Companies Bullish On 2014

Jim-044

The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

A New Addition to Pennsylvania Bio’s Leadership Team

ct-115x76

To effectively achieve our mission as the champion and advocate of biotechnology, BIO works with a broad network of organizations. Foremost among these relationships are the ones we possess with a broad network of state-based organizations known as the Council of State Bioscience Associations (CSBA). Pennsylvania Bio (PA Bio) has been a key ally to BIO and vocal advocate for state and federal public policy in support of the biotechnology industry since our inception. Just Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,